These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 26747278)

  • 1. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.
    Chen HC; Huang CD; Chang E; Kuo HP
    BMC Pulm Med; 2016 Jan; 16():3. PubMed ID: 26747278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
    Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
    Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.
    Grimaldi-Bensouda L; Zureik M; Aubier M; Humbert M; Levy J; Benichou J; Molimard M; Abenhaim L;
    Chest; 2013 Feb; 143(2):398-405. PubMed ID: 23505637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
    Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
    Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
    Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
    BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland.
    Subramaniam A; Al-Alawi M; Hamad S; O'Callaghan J; Lane SJ
    QJM; 2013 Jul; 106(7):631-4. PubMed ID: 23550166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland.
    Jahnz-Różyk K; Lis J; Warchoł M; Kucharczyk A
    BMC Pulm Med; 2018 Mar; 18(1):48. PubMed ID: 29548318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
    Chipps BE; Figliomeni M; Spector S
    Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
    Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
    Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience.
    Sposato B; Scalese M; Latorre M; Scichilone N; Matucci A; Milanese M; Masieri S; Rolla G; Steinhilber G; Rosati Y; Vultaggio A; Folletti I; Baglioni S; Bargagli E; Di Tomassi M; Pio R; Pio A; Maccari U; Maggiorelli C; Migliorini MG; Vignale L; Pulerà N; Carpagnano GE; Foschino Barbaro MP; Perrella A; Paggiaro PL
    Respir Med; 2016 Oct; 119():141-149. PubMed ID: 27692136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma.
    Tadrous M; Khuu W; Lebovic G; Stanbrook MB; Martins D; Paterson JM; Mamdani MM; Juurlink DN; Gomes T
    Ann Allergy Asthma Immunol; 2018 Jan; 120(1):59-65.e2. PubMed ID: 28986124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma.
    Grossman HL; Schlender A; Alperin P; Stanley EL; Zhang J
    Curr Med Res Opin; 2010 Dec; 26(12):2779-93. PubMed ID: 21050061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
    Chen H; Eisner MD; Haselkorn T; Trzaskoma B
    Respir Med; 2013 Jan; 107(1):60-7. PubMed ID: 23083840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
    Zafari Z; Sadatsafavi M; Marra CA; Chen W; FitzGerald JM
    PLoS One; 2016; 11(1):e0146003. PubMed ID: 26751790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
    Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
    Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
    Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
    Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
    Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.